Stocks moved lower after Federal Reserve Chair Jerome Powell said the central bank is in 'no hurry' on rate cuts.

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...